Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
| Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) | ||
| Sanofi Head of Global R&D Elias Zerhouni to retire; Company names John Reed to take over on July 1 Paris - 24th April 2018 -- Elias Zerhouni, M.D., Head of Global Research and Development will retire from Sanofi on June 30th, 2018, after more than 9 years of distinguished service with the company. He will be succeeded in the post by John C. Reed, M.D. Ph.D. who has been appointed Head of Global Research & Development, as of July 1st, 2018. Dr. Zerhouni joined Sanofi in 2009 as scientific advisor to the Chief Executive Officer and was appointed to his current post in January 2011. "Throughout his tenure at Sanofi, Elias has relentlessly and passionately strived to transform Sanofi R&D into an organization with the potential to be one of the very best in the industry. We are grateful for his outstanding contributions to Sanofi and wishing him all the best for the future," said Sanofi Chief Executive Officer Olivier Brandicourt, M.D. Appointment of John C. Reed Dr. Reed will report directly to Dr. Brandicourt and will be a member of the Executive Committee. He will join Sanofi on April 30th to ensure a smooth and effective transition period. "John is an accomplished and widely recognized physician-scientist with a brilliant academic track record," said Dr. Brandicourt. "He is experienced in driving R&D productivity, building high-performing teams and integrating biotech companies to provide new technology platforms." For the past five years Dr. Reed has served as the Global Head of Roche Pharma Research & Early Development (pRED), responsible for directing research and early development activities through Phase 2b proof-of-concept (PoC) across all therapeutic areas, including oncology, immunology, rare diseases, neuroscience, ophthalmology and infectious diseases. He was also a member of Roche's Corporate Executive Committee, reporting to the CEO. Dr. Reed holds a B.A in chemistry from the University of Virginia, Charlottesville and a M.D. PhD. from the University of Pennsylvania, School of Medicine where he began his academic career at the University in 1988, following a post-doctoral fellowship in Molecular Biology at the Wistar Institute and a residency in Pathology & Laboratory Medicine at Hospital of University Pennsylvania. He then joined the Burnham Institute in 1992, one of the best known biomedical research institutes in the U.S, where he held multiple positions of increasing responsibility such as Program Director of the NCI-designated Cancer Center, Scientific Director, and Director of the Cancer Center. In 2002 he was appointed President and CEO of the Sanford-Burnham Medical Research Institute. | ||
| About Sanofi Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. Sanofi, Empowering Life | ||
| Media Relations Contacts Jack Cox Tel.: +33 (0)1 53 77 46 46 [email protected] Ashleigh Koss (United States) Tel.: +1 (908) 205-2572 [email protected] | Investor Relations Contact George Grofik Tel.: +33 (0)1 53 77 45 45 [email protected] | |
Attachment
